Physician

Angela Rose Vanlandingham, M.D.

According to 2025 Medicare claims, Angela Vanlandingham, M.D. (NPI: 1538331939) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Hanover, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23116-3834.

Vanlandingham's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 676 traditional Medicare patients, billed 105,777 HCPCS/CPT codes, and received $2,351,076 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,118 prescription claims across 164 beneficiaries totaling $3,054,556 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 15 claims. Open Payments data shows 56 records totaling $1,361. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $8,801 to $2,351,076. Similarly, Part D prescription costs have moved sharply higher in recent years, from $5,467 to $3,054,556. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	44	203	$8,801
2016	323	2,777	$84,369
2017	263	2,451	$90,638
2018	549	79,456	$1,004,775
2019	754	148,231	$1,997,836
2020	687	96,966	$1,713,602
2021	687	106,265	$1,788,980
2022	702	148,034	$2,484,228
2023	718	156,409	$2,355,400
2024	676	105,777	$2,351,076

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	18	55	$5,467
2016	78	257	$65,394
2017	71	282	$220,743
2018	98	398	$726,910
2019	108	617	$1,256,748
2020	114	786	$1,625,880
2021	117	699	$1,645,523
2022	135	785	$1,605,974
2023	150	978	$2,633,182
2024	164	1,118	$3,054,556

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	15	$288
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	147	316	$133
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	284	423	$87
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	96	151	$44
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	217	279	$13
96372	Injection of drug or substance under skin or into muscle	126	433	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	34	861	$579,884
Brukinsa	Zanubrutinib	32	960	$445,373
Calquence	Acalabrutinib Maleate	22	660	$299,014
Welireg	Belzutifan	12	360	$260,782
Cabometyx	Cabozantinib S-Malate	11	330	$248,899

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	56	$1,361	Astellas Pharma US Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Angela Rose Vanlandingham, M.D.?

Tedicare shows public-source Medicare data for Angela Rose Vanlandingham, M.D. (NPI 1538331939), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Angela Rose Vanlandingham, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Angela Rose Vanlandingham, M.D.?

Angela Rose Vanlandingham, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Angela Rose Vanlandingham, M.D. have Open Payments data?

Angela Rose Vanlandingham, M.D. has 56 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.